How and where to order Tegretol (Carbamazepine) 100 mg, 200 mg, 400 mg tablets online:
|DFH PHARMACY - 10% discount coupon DFH10
|from $0.45 per pill
|100 mg, 200 mg, 400 mg tablets or capsules
|Carbamazepine brand, Tegretol generic
|Visa, Mastercard, AmEx, Bitcoin
|Regular and express mail service
|Worldwide, including USA, UK, Europe, Canada, Australia
Indications and usage:
Tegretol (Carbamazepine) is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of this medication as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types:
1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types.
2. Generalized tonic-clonic seizures (grand mal).
3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by Tegretol.
Tegretol is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia, occipital neuralgia, diabetic neuropathy, to relief pain in the throat, tongue and other neuropathic pain. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.
Carbamazepine is also used for the therapy of dystonia, cyclothymic disorder, borderline personality disorder, attention deficit hyperactivity disorder, cluster-tic syndrome, reflex sympathetic dystrophy syndrome, for adjunctive treatment in schizophrenia and schizoaffective disorder, as a second-line medicine in bipolar disorder.
Dosage and administration:
Tegretol (Carbamazepine) suspension in combination with liquid chlorpromazine or thioridazine results in precipitate formation, and, in the case of chlorpromazine, there has been a report of a patient passing an orange rubbery precipitate in the stool following coadministration of the two drugs. Because the extent to which this occurs with other liquid medications is not known, Tegretol suspension should not be administered simultaneously with other liquid medications or diluents.
Dosage should be adjusted to the needs of the individual patient. A low initial daily dosage with a gradual increase is advised. As soon as adequate control is achieved, the dosage may be reduced very gradually to the minimum effective level. Medication should be taken with meals.
Since a given dose of Tegretol suspension will produce higher peak levels than the same dose given as the tablet, it is recommended to start with low doses (children 6 to 12 years: ? teaspoon four times a day and to increase slowly to avoid unwanted side effects.
Conversion of patients from oral Tegretol tablets to Tegretol suspension: Patients should be converted by administering the same number of mg per day in smaller, more frequent doses (i.e., twice a day tablets to three times a day suspension).
Tegretol-XR (Carbamazepine) is an extended-release formulation for twice a day administration. When converting patients from Tegretol conventional tablets to Tegretol-XR, the same total daily mg dose of Tegretol-XR should be administered. Tegretol-XR tablets must be swallowed whole and never crushed or chewed. Tegretol-XR tablets should be inspected for chips or cracks. Damaged tablets, or tablets without a release portal, should not be consumed. Tegretol-XR tablet coating is not absorbed and is excreted in the feces; these coatings may be noticeable in the stool.
Signs and symptoms
The first signs and symptoms of carbamazepine overdosage appear after 1 to 3 hours. Neuromuscular disturbances are the most prominent. Cardiovascular disorders are generally milder, and severe cardiac complications occur only when very high doses (greater than 60 g) have been ingested.
The prognosis in cases of severe poisoning is critically dependent upon prompt elimination of the drug, which may be achieved by inducing vomiting, irrigating the stomach, and by taking appropriate steps to diminish
absorption. If these measures cannot be implemented without risk on the spot, the patient should be transferred at once to a hospital, while ensuring that vital functions are safeguarded. There is no specific antidote.
Dosage forms and strengths:
Tegretol (Carbamazepine) tablets 200 mg - capsule-shaped, pink, single-scored (imprinted Tegretol on one side and 27 twice on the partially scored side).
Tegretol (Carbamazepine) chewable tablets 100 mg - round, red-speckled, pink, single-scored (imprinted Tegretol on one side and 52 twice on the scored side).
Tegretol-XR (Carbamazepine) tablets 100 mg - round, yellow, coated (imprinted T on one side and 100 mg on the other), release portal on one side.
Tegretol-XR (Carbamazepine) tablets 200 mg - round, pink, coated (imprinted T on one side and 200 mg on the other), release portal on one side.
Tegretol-XR (Carbamazepine) tablets 400 mg - round, brown, coated (imprinted T on one side and 400 mg on the other), release portal on one side.
Tegretol (Carbamazepine) suspension 100 mg / 5 ml (teaspoon) - yellow-orange, citrus-vanilla flavored Bottles of 450 ml.
Carbamazepine (Tegretol) should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. Likewise, on theoretical grounds its use with monoamine oxidase (MAO) inhibitors is not recommended. Before administration of Tegretol, MAO inhibitors should be discontinued for aminimum of 14 days, or longer if the clinical situation permits.
Coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. Coadministration of carbamazepine with nefazodone is contraindicated.
Warnings and precautions:
Serious dermatologic reactions: serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), have been reported with Tegretol treatment.
SJS/TEN and HLA-B*1502 allele: retrospective case-control studies have found that in patients of chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502.
Prior to initiating Tegretol therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present.
Hypersensitivity reactions and HLA-A*3101 allele: retrospective case-control studies in patients of european, korean, and japanese ancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence of HLA-A*3101, an inherited allelic variant of the HLA-A gene, in patients using carbamazepine.
Aplastic anemia and agranulocytosis: aplastic anemia and agranulocytosis have been reported in association with the use of Tegretol. Patients with a history of adverse hematologic reaction to any drug may be particularly at risk of bone marrow depression.
Drug reaction with eosinophilia and systemic symptoms (dress)/multiorgan hypersensitivity.
Hypersensitivity reactions to carbamazepine have been reported in patients who previously experienced this reaction to anticonvulsants including phenytoin, primidone, and phenobarbital.
Rare cases of anaphylaxis and angioedema involving the larynx, glottis, lips, and eyelids have been reported in patients after taking the first or subsequent doses of Tegretol.
Suicidal behavior and ideation: antiepileptic drugs (AEDs), including Tegretol, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.
Adverse reactions, side effects:
If adverse reactions are of such severity that the drug must be discontinued, the physician must be aware that abrupt discontinuation of any anticonvulsant drug in a responsive epileptic patient may lead to seizures or even status epilepticus with its life-threatening hazards.
The most severe adverse reactions have been observed in the hemopoietic system and skin, the liver, and the cardiovascular system.
The most frequently observed adverse reactions, particularly during the initial phases of therapy, are dizziness, drowsiness, unsteadiness, nausea, and vomiting. To minimize the possibility of such reactions, therapy should be initiated at the lowest dosage recommended.
To report suspected side effects of Tegretol (Carbamazepine) tablets contact Novartis pharmaceutical company or your local FDA.
Agents that may affect Tegretol plasma levels: when carbamazepine is given with drugs that can increase or decrease carbamazepine levels, close monitoring of carbamazepine levels is indicated and dosage adjustment may be required.
Effect of this medicine on plasma levels of concomitant agents: decreased levels of concomitant medications.
There is a potential for increased cyclophosphamide toxicity when coadministered with carbamazepine.
Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
Concomitant use of Tegretol and isoniazid has been reported to increase isoniazid-induced hepatotoxicity.
Alterations of thyroid function have been reported in combination therapy with other anticonvulsant medications.
Concomitant use of this drug with hormonal contraceptive products (e.g., oral, and levonorgestrel subdermal implant contraceptives) may render the contraceptives less effective because the plasma concentrations of the hormones may be decreased.
Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine.
Concomitant use of Tegretol with rivaroxaban, apixaban, dabigatran, and edoxaban (direct acting oral anticoagulants) is expected to result in decreased plasma concentrations of these anticoagulants that may be insufficient to achieve the intended therapeutic effect. In general, coadministration of carbamazepine with rivaroxaban, apixaban, dabigatran, and edoxaban should be avoided.
Gabapentin 300 mg
Use in specific populations:
Carbamazepine can cause fetal harm when administered to a pregnant woman.
Because of the potential for serious adverse reactions in nursing infants from carbamazepine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The evidence assembled was primarily obtained from short-term use of carbamazepine. The safety of this medication in children has been systematically studied up to 6 months. No longer-term data from clinical trials is available.
No systematic studies in geriatric patients have been conducted.
Labor and delivery
The effect of Tegretol (Carbamazepine) tablets on human labor and delivery is unknown.
Information for patients:
Patients should be informed of the availability of a medication guide and they should be instructed to read the medication guide before taking Tegretol (Carbamazepine) pills.
Patients should be made aware of the early toxic signs and symptoms of a potential hematologic problem, as well as dermatologic, hypersensitivity or hepatic reactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy and petechial or purpuric hemorrhage, and in the case of liver reactions, anorexia, nausea/vomiting, or jaundice. The patient should be advised that, because these signs and symptoms may signal a serious reaction, that they must report any occurrence immediately to a physician. In addition, the patient should be advised that these signs and symptoms should be reported even if mild or when occurring after extended use.
Patients should be advised that serious skin reactions have been reported in association with Tegretol. In the event a skin reaction should occur while taking this medicine, patients should consult with their physician immediately.
Patients should be advised that anaphylactic reactions and angioedema may occur during treatment with carbamazepine. Advise patients to immediately report signs and symptoms suggesting angioedema (swelling of the face, eyes, lips, or tongue, or difficulty in swallowing or breathing) and to stop taking the drug until they have consulted with their healthcare provider.
Patients, their caregivers, and families should be counseled that AEDs, including Tegretol, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
This drug may interact with some others. Therefore, patients should be advised to report to their doctors the use of any other prescription or nonprescription medications or herbal products.
Caution should be exercised if alcohol is taken in combination with Tegretol therapy, due to a possible additive sedative effect.
Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging in other potentially dangerous tasks.
Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant.
This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 in the USA.
Drug abuse and dependence:
No evidence of abuse potential has been associated with Tegretol (Carbamazepine) pills, nor is there evidence of psychological or physical dependence in humans.
Where to buy carbamazepine online:
To purchase Tegretol (Carbamazepine) 100 mg, 200 mg, 400 mg capsules or tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing carbamazepine as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
|Pharmaceutical forms and doses
|Capsules; Extended Release; Oral; Carbamazepine 100 mg, 200 mg, 300 mgSuspension; Oral; Carbamazepine 100 mg / 5 mlTablets; Oral; Carbamazepine 200 mg, 400 mg
|Tablets, Chewable; Oral; Carbamazepine 100 mgTablets; Oral; Carbamazepine 200 mg
|Capsules; Oral; Carbamazepine 200 mgTablets; Oral; Carbamazepine 200 mg, 400 mg
|Gerot PharmazeutikaGreen Cross CorporationHorna Business ServiceOrion Pharma
|Solution; Oral; Carbamazepine 100 mg / 5 mlSuppositories; Rectal; Carbamazepine 125 mg, 250 mgSuspension; Oral; Carbamazepine 100 mg / 5 mlSyrup; Oral; Carbamazepine 100 mg / 5 mlTablets, Chewable; Oral; Carbamazepine 100 mg, 200 mgTablets, Controlled Release; Oral; Carbamazepine 200 mgTablets; Oral; Carbamazepine 200 mg, 400 mg
|Tablets, Extended Release; Oral; Carbamazepine 100 mg, 200 mg, 400 mg
|Tablets; Oral; Carbamazepine 100 mg, 200 mg, 400 mgTablets, Prolonged Release; Oral; Carbamazepine 200 mg, 300 mg, 400 mg
|Sun Pharmaceutical Industries